Piper Sandler Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price

Amneal Pharmaceuticals (NASDAQ:AMRX) had its price target increased by Piper Sandler from $9.00 to $11.00 in a research report sent to investors on Monday,Benzinga reports. They currently have an overweight rating on the stock.

AMRX has been the subject of several other reports. Truist Financial lifted their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. Barclays lifted their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of “Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Trading Down 0.3 %

Shares of NASDAQ AMRX opened at $9.00 on Monday. Amneal Pharmaceuticals has a 12 month low of $4.16 and a 12 month high of $9.48. The stock has a 50 day moving average of $8.56 and a 200-day moving average of $7.62. The company has a market capitalization of $2.79 billion, a P/E ratio of -13.28 and a beta of 1.17.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Profund Advisors LLC raised its holdings in Amneal Pharmaceuticals by 8.1% in the 2nd quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock valued at $143,000 after acquiring an additional 1,680 shares in the last quarter. ProShare Advisors LLC raised its holdings in Amneal Pharmaceuticals by 8.6% in the 1st quarter. ProShare Advisors LLC now owns 21,902 shares of the company’s stock valued at $133,000 after acquiring an additional 1,726 shares in the last quarter. SG Americas Securities LLC raised its holdings in Amneal Pharmaceuticals by 18.8% in the 1st quarter. SG Americas Securities LLC now owns 20,112 shares of the company’s stock valued at $122,000 after acquiring an additional 3,177 shares in the last quarter. Rothschild Investment LLC acquired a new position in Amneal Pharmaceuticals in the 2nd quarter valued at $26,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Amneal Pharmaceuticals by 13.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock valued at $222,000 after acquiring an additional 4,115 shares in the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.